Leerink Partners Maintains Quanterix(QTRX.US) With Buy Rating
Leerink Partners Sticks to Its Buy Rating for Quanterix (QTRX)
Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Doximity (DOCS) and Warby Parker (WRBY)
Quanterix Analyst Ratings
Quanterix Price Target Cut to $28.00/Share From $32.00 by Scotiabank
Scotiabank Keeps Their Buy Rating on Quanterix (QTRX)
Quanterix Analyst Ratings
TD Cowen Maintains Hold on Quanterix, Lowers Price Target to $15
Hold Rating on Quanterix Amid Modest Sales Performance and Market Uncertainty
Analysts' Top Healthcare Picks: Trevi Therapeutics (TRVI), Quanterix (QTRX)
Scotiabank Maintains Quanterix(QTRX.US) With Buy Rating, Maintains Target Price $32
Goldman Sachs Adjusts Price Target on Quanterix to $24 From $35, Maintains Buy Rating
Quanterix Analyst Ratings
Goldman Sachs Maintains Buy on Quanterix, Lowers Price Target to $24
Outperform Rating and $30 Price Target for Quanterix Amid Strong Position in Alzheimer's Diagnostics Market
Scotiabank Reaffirms Their Buy Rating on Quanterix (QTRX)
Buy Rating on Quanterix: Strong Performance and Growth Potential Amid Competitive Market
Canaccord Genuity Adjusts Price Target on Quanterix to $25 From $32, Maintains Buy Rating
Canadian Investment Banking Group: Maintaining the Quanterix (QTRX.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $32.00 to $25.00.
Quanterix Analyst Ratings